Literature DB >> 25353059

Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology.

Olaf Scheel1, Stefanie Frech, Bogdan Amuzescu, Jörg Eisfeld, Kun-Han Lin, Thomas Knott.   

Abstract

Recent progress in embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) research led to high-purity preparations of human cardiomyocytes (CMs) differentiated from these two sources-suitable for tissue regeneration, in vitro models of disease, and cardiac safety pharmacology screening. We performed a detailed characterization of the effects of nifedipine, cisapride, and tetrodotoxin (TTX) on Cor.4U(®) human iPSC-CM, using automated whole-cell patch-clamp recordings with the CytoPatch™ 2 equipment, within a complex assay combining multiple voltage-clamp and current-clamp protocols in a well-defined sequence, and quantitative analysis of several action potential (AP) parameters. We retrieved three electrical phenotypes based on AP shape: ventricular, atrial/nodal, and S-type (with ventricular-like depolarization and lack of plateau). To suppress spontaneous firing, present in many cells, we injected continuously faint hyperpolarizing currents of -10 or -20 pA. We defined quality criteria (both seal and membrane resistance over 1 GΩ), and focused our study on cells with ventricular-like AP. Nifedipine induced marked decreases in AP duration (APD): APD90 (49.8% and 40.8% of control values at 1 and 10 μM, respectively), APD50 (16.1% and 12%); cisapride 0.1 μM increased APD90 to 176.2%; and tetrodotoxin 10 μM decreased maximum slope of phase to 33.3% of control, peak depolarization potential to 76.3% of control, and shortened APD90 on average to 80.4%. These results prove feasibility of automated voltage- and current-clamp recordings on human iPSC-CM and their potential use for in-depth drug evaluation and proarrhythmic liability assessment, as well as for diagnosis and pharmacology tests for cardiac channelopathy patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25353059     DOI: 10.1089/adt.2014.601

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  24 in total

1.  Rigorous Phenotyping of Cardiac iPSC Preparations Requires Knowledge of Their Resting Potential(s).

Authors:  Wayne R Giles; Denis Noble
Journal:  Biophys J       Date:  2016-01-05       Impact factor: 4.033

2.  Light-Activated Dynamic Clamp Using iPSC-Derived Cardiomyocytes.

Authors:  Bonnie Quach; Trine Krogh-Madsen; Emilia Entcheva; David J Christini
Journal:  Biophys J       Date:  2018-10-30       Impact factor: 4.033

3.  Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.

Authors:  Corina T Bot; Krisztina Juhasz; Fabian Haeusermann; Liudmila Polonchuk; Martin Traebert; Sonja Stoelzle-Feix
Journal:  J Pharmacol Toxicol Methods       Date:  2018-06-22       Impact factor: 1.950

Review 4.  Evolution of strategies to improve preclinical cardiac safety testing.

Authors:  Gary Gintant; Philip T Sager; Norman Stockbridge
Journal:  Nat Rev Drug Discov       Date:  2016-02-19       Impact factor: 84.694

Review 5.  Perspectives and Challenges of Pluripotent Stem Cells in Cardiac Arrhythmia Research.

Authors:  Alexander Goedel; Ilaria My; Daniel Sinnecker; Alessandra Moretti
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

6.  Yohimbine Directly Induces Cardiotoxicity on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Yiqi Gong; Li Yang; Jun Tang; Jijian Zheng; Nevin Witman; Philipp Jakob; Yao Tan; Minglu Liu; Ying Chen; Huijing Wang; Wei Fu; Wei Wang
Journal:  Cardiovasc Toxicol       Date:  2021-11-24       Impact factor: 3.231

Review 7.  Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes.

Authors:  Fikru B Bedada; Matthew Wheelwright; Joseph M Metzger
Journal:  Biochim Biophys Acta       Date:  2015-11-11

Review 8.  Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.

Authors:  Alec S T Smith; Jesse Macadangdang; Winnie Leung; Michael A Laflamme; Deok-Ho Kim
Journal:  Biotechnol Adv       Date:  2016-12-20       Impact factor: 14.227

Review 9.  Optogenetic Approaches to Drug Discovery in Neuroscience and Beyond.

Authors:  Hongkang Zhang; Adam E Cohen
Journal:  Trends Biotechnol       Date:  2017-05-25       Impact factor: 19.536

Review 10.  Next generation of heart regenerative therapies: progress and promise of cardiac tissue engineering.

Authors:  Miguel F Tenreiro; Ana F Louro; Paula M Alves; Margarida Serra
Journal:  NPJ Regen Med       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.